Drug and skin care maker Valeant Pharmaceuticals is in the news these days for all the wrong reasons. First, Valeant got pulled into the debate on drug pricing. Lawmakers are investigating the company’s practice of buying drugs through corporate M&A and jacking up their prices, a strategy that Valeant will now rein in, according to company executives.   Valeant also is being scrutinized for its use of previously undisclosed specialty pharmacies to sell drugs. An over 70% tumble in its st...